Éric Baudin

Active 1990–2025

Also published as
Eric Baudin
189
Papers
34,019
Citations
105
h-index
186
i10-index

Citations

Citations per year for Éric Baudin1984: 1 citations1993: 2 citations1994: 1 citations1995: 5 citations1996: 3 citations1997: 5 citations1998: 10 citations1999: 15 citations2000: 26 citations2001: 49 citations2002: 47 citations2003: 38 citations2004: 75 citations2005: 61 citations2006: 101 citations2007: 106 citations2008: 112 citations2009: 186 citations2010: 179 citations2011: 182 citations2012: 270 citations2013: 277 citations2014: 264 citations2015: 290 citations2016: 221 citations2017: 287 citations2018: 292 citations2019: 1,034 citations2020: 1,111 citations2021: 980 citations2022: 717 citations2023: 547 citations2024: 913 citations2025: 393 citations2026: 7 citations1985–1992: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,000 citing papers, 21% of this breakdownItaly: 971 citing papers, 10.2% of this breakdownFrance: 850 citing papers, 8.9% of this breakdownGermany: 714 citing papers, 7.5% of this breakdownUnited Kingdom: 534 citing papers, 5.6% of this breakdownChina: 514 citing papers, 5.4% of this breakdownNetherlands: 411 citing papers, 4.3% of this breakdownSwitzerland: 292 citing papers, 3.1% of this breakdownCanada: 281 citing papers, 3% of this breakdownSpain: 264 citing papers, 2.8% of this breakdownAustralia: 242 citing papers, 2.6% of this breakdownSweden: 228 citing papers, 2.4% of this breakdown
0%21%Other 23.2%

Fields

  • Medicine88.8%
  • Biochemistry, Genetics and Molecular Biology9.4%
  • Computer Science0.2%
  • Immunology and Microbiology0.2%
  • Neuroscience0.2%
  • Nursing0.2%
  • Other1%

Topics

  • Neuroendocrine Tumor Research Advances10.7%
  • Thyroid Cancer Diagnosis and Treatment9.8%
  • Adrenal and Paraganglionic Tumors7.3%
  • Lung Cancer Research Studies6.7%
  • Neuroblastoma Research and Treatments5%
  • Cancer, Hypoxia, and Metabolism4.3%
  • Other56.2%

Coauthors

All papers

Open in search
  1. Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , L. Sylvia, Richard J. Auchus, J. Todd Auman, Robert Baertsch, Miruna Balasundaram, Saianand Balu, Detlef K. Bartsch, Éric Baudin, Thomas Bauer, Allison Beaver, Christopher C. Benz, Rameen Beroukhim, Felix Beuschlein, Tom Bodenheimer, Lori Boice, Jay Bowen, Reanne Bowlby, Denise Brooks, Rebecca Carlsen, Suzie Carter, Clarissa A. Cassol, Andrew D. Cherniack, Lynda Chin, Juok Cho, Eric Chuah, Sudha Chudamani, Leslie Cope, Daniel Crain, Erin Curley, Ludmila Danilova, Aguirre A. de Cubas, Ronald R. de Krijger, John A. Demchok, Timo Deutschbein, Noreen Dhalla, David Dimmock, Winand N.M. Dinjens, Tobias Else, Charis Eng, Jennifer Eschbacher, Martin Faßnacht, Ina Felau, Michael D. Feldman, Martin L. Ferguson, Ian T. Fiddes, Lauren Fishbein, Scott Frazer, Stacey Gabriel, Johanna Gardner, Julie M. Gastier‐Foster, Nils Gehlenborg, Mark Gerken, Gad Getz, Jennifer L. Geurts, Hans K. Ghayee, Anne‐Paule Gimenez‐Roqueplo, Thomas J. Giordano, Mary J. Goldman, Kiley Graim, Manaswi Gupta, David Haan, Stefanie Hahner, Constanze Hantel, David Haussler, D. Neil Hayes, David I. Heiman, Katherine A. Hoadley, Robert A. Holt, Alan P. Hoyle, Mei Huang and 132 more - Cancer Cell 2017 cited by 783

  2. Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

    Authors: , , , , , , , , , , , , , - Journal of Clinical Oncology 2011 cited by 1,550

  3. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors

    Authors: , , , , , , , , , - European Journal of Endocrinology 2018 cited by 941

  4. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Authors: , , , , , , , , , - Annals of Oncology 2020 cited by 420

  5. Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial

    Authors: , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2022 cited by 139

  6. Combination Chemotherapy in Advanced Adrenocortical Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hanneke Wilmink, Monica Sender, Maureen Edgerly, W. Kenn, Tito Fojo, Hans‐Helge Müller, Britt Skogseid - New England Journal of Medicine 2012 cited by 864

  7. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , James C. Yao - European Journal of Cancer 2021 cited by 242

  8. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Emmanuel Mitry, M. Nicolson, Juan Manuel O’Connor, Dermot O’Toole, Ulrich-Frank Pape, Marianne Pavel, John Ramage, Éric Raymond, Guido Rindi, Andrea Rockall, Philippe Ruszniewski, Ramón Salazar, Aldo Scarpa, Eva Sedláčková, Anders Sundin, Christos Toumpanakis, Marie‐Pierre Vullierme, Wolfgang Weber, Bertram Wiedenmann, Zeng Zheng-Pei - Annals of Oncology 2015 cited by 699

  9. International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Reviews Endocrinology 2021 cited by 163

  10. Anaplastic Thyroid Carcinoma: An Update

    Authors: , , , , , , , , , , , , - Cancers 2022 cited by 151

  11. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

    Authors: , , , , , , , , , , , , - The Lancet 2011 cited by 1,052

  12. Integrated genomic characterization of adrenocortical carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Felix Beuschlein, Rossella Libé, Aurélien de Reyniès, Jérôme Bertherat - Nature Genetics 2014 cited by 733

  13. Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

    Authors: , , , , , , , , , , , , , , , , - Annals of Oncology 2021 cited by 256

  14. Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Isabelle Borget, Éric Baudin, European Network for the Study of Adrenal Tumors (ENS@T) - The Journal of Clinical Endocrinology & Metabolism 2019 cited by 180

  15. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging

    Authors: , , , , , , , , , , , , , , , , , , , - Neuroendocrinology 2017 cited by 497

  16. Clinical activity of CC‐90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies

    Authors: , , , , , , , , , , , , , , , , , , , - Cancer 2022 cited by 49

  17. International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 cited by 137

  18. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas

    Authors: , , , , , , , , , , , , , - Neuroendocrinology 2016 cited by 606

  19. Major Prognostic Role of Ki67 in Localized Adrenocortical Carcinoma After Complete Resection

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Journal of Clinical Endocrinology & Metabolism 2015 cited by 335

  20. Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Frédéric Castinetti, Jérôme Bertherat, Rossella Libé, Anne‐Paule Gimenez‐Roqueplo, Judith Favier, Marcus Quinkler, Christian J. Strasburger, Katrin Zopf, Martín Reincke, Matthias Kroiß, Hanna Remde, Michaela Haaf, Carmina Teresa Fuß, Ulrich Dischinger, Graeme Eisenhofer, Christina Pamporaki, Anouk van Berkel - The Lancet 2024 cited by 66

  21. ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary

    Authors: , , , , , , , , - Neuroendocrinology 2012 cited by 870

  22. MANAGEMENT OF ENDOCRINE DISEASE: Cushing’s syndrome due to ectopic ACTH secretion: an expert operational opinion

    Authors: , , , , , - European Journal of Endocrinology 2020 cited by 226

  23. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma

    Authors: , , , , , , , , , , , , , , , , , , , - International Journal of Cancer 2014 cited by 204

  24. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study

    Authors: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2015 cited by 333